Company intelligence / Profile preview
Transcend Therapeutics
New York, New York, United Statestranscendtherapeutics.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Transcend's lead compound TSND-201 (methylone) met its primary endpoint in the IMPACT-1 Phase 2 clinical trial for PTSD, demonstrating statistically significant placebo-adjusted CAPS-5 improvement of -9.64 points on Day 64 (p = 0.011) and rapid improvements with statistically significant placebo-adjusted CAPS-5 improvement of -8.00 points on Day 10 (p = 0.012). The drug was generally safe and well-tolerated.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small molecules (neuroplastogens)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Transcend Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Transcend Therapeutics.